Timothy P Flanigan

Author PubWeight™ 99.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005 4.96
2 Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002 3.27
3 Feasibility and acceptability of rapid HIV testing in jail. AIDS Patient Care STDS 2007 2.52
4 It is time to implement routine, not risk-based, HIV testing. Clin Infect Dis 2005 2.40
5 Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2002 2.39
6 Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006 2.30
7 HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011 1.97
8 Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004 1.97
9 The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005 1.95
10 The importance of routine HIV testing in the incarcerated population: the Rhode Island experience. AIDS Educ Prev 2002 1.91
11 A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007 1.83
12 Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge. J Health Care Poor Underserved 2008 1.81
13 Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002 1.76
14 Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006 1.72
15 Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002 1.71
16 Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS 2011 1.63
17 Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007 1.56
18 The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005 1.46
19 Clinical profile of HIV in India. Indian J Med Res 2005 1.41
20 A diagnostic dilemma in a patient receiving antiretroviral and antituberculosis therapy. AIDS Read 2005 1.38
21 Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007 1.34
22 Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav 2013 1.33
23 Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 2005 1.29
24 The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003 1.27
25 Unprotected sex with multiple partners: implications for HIV prevention among young men with a history of incarceration. Sex Transm Dis 2006 1.26
26 A success story: HIV prevention for injection drug users in Rhode Island. Subst Abuse Treat Prev Policy 2006 1.26
27 Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008 1.26
28 The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS 2003 1.24
29 Apathy correlates with cognitive function but not CD4 status in patients with human immunodeficiency virus. J Neuropsychiatry Clin Neurosci 2005 1.18
30 Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2004 1.13
31 Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr 2011 1.10
32 HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis 2013 1.07
33 A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 2003 1.06
34 Acceptability of sexually transmitted infection screening among women in short-term substance abuse treatment. Sex Transm Dis 2002 1.04
35 Initial outcomes of an emergency department rapid HIV testing program in western Kenya. AIDS Patient Care STDS 2007 1.03
36 Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav 2013 1.02
37 Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr 2011 1.02
38 Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health 2014 0.99
39 Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis 2002 0.97
40 Young incarcerated men's perceptions of and experiences with HIV testing. Am J Public Health 2007 0.97
41 Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS 2005 0.95
42 Lessons learned from family-centred models of treatment for children living with HIV: current approaches and future directions. J Int AIDS Soc 2010 0.95
43 HIV-positive and in jail: race, risk factors, and prior access to care. AIDS Behav 2013 0.95
44 Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr 2011 0.94
45 Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003 0.91
46 Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release. AIDS Behav 2013 0.91
47 Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One 2013 0.91
48 Routine HIV testing among inpatients. Arch Intern Med 2002 0.89
49 HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002 0.89
50 HIV risk behavior before and after HIV counseling and testing in jail: a pilot study. J Acquir Immune Defic Syndr 2010 0.88
51 Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005 0.87
52 Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. J Int Assoc Physicians AIDS Care (Chic) 2011 0.85
53 Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One 2010 0.84
54 Short communication: new HIV infections at Southern New England academic institutions: implications for prevention. AIDS Res Hum Retroviruses 2012 0.84
55 Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007. Med Health R I 2009 0.83
56 The intertwined epidemics of HIV infection, incarceration, and substance abuse: a call to action. J Infect Dis 2011 0.83
57 Follow-up care among HIV-infected pregnant women in Mississippi. J Womens Health (Larchmt) 2010 0.82
58 Racial/ethnic attitudes towards HIV testing in the primary care setting. J Natl Med Assoc 2005 0.82
59 Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. Clin Infect Dis 2011 0.81
60 Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med 2012 0.81
61 Monitoring HIV treatment in the developing world. Lancet Infect Dis 2002 0.80
62 HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City. AIDS Res Treat 2011 0.80
63 Community-based interventions for marginalized populations. Clin Infect Dis 2004 0.80
64 Small reservoirs: jail screening for gonorrhea and Chlamydia in low prevalence areas. J Correct Health Care 2009 0.79
65 Directly observed therapy (DOT) for individuals with HIV: successes and challenges. MedGenMed 2003 0.79
66 HIV among marginalized populations in Rhode Island. Med Health R I 2009 0.79
67 Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care 2012 0.78
68 Routine HIV testing in jails is critical for the early diagnosis of HIV infection in men. Clin Infect Dis 2008 0.78
69 Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients. AIDS Patient Care STDS 2004 0.78
70 Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. AIDS 2003 0.78
71 The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult. Clin Infect Dis 2006 0.77
72 Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye? Clin Infect Dis 2013 0.77
73 Routine HIV testing in US prisons. Lancet Infect Dis 2007 0.76
74 Directly observed therapy for HIV/tuberculosis co-infection. Lancet Infect Dis 2004 0.76
75 Public health principles for the HIV epidemic. N Engl J Med 2006 0.75
76 Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir. AIDS 2006 0.75
77 Outpatient parenteral antibiotic therapy in an academic practice in Rhode Island. R I Med J (2013) 2014 0.75
78 The extraordinary hope of antiretroviral therapy in South Africa (even for patients with tuberculosis or kaposi sarcoma!). J Infect Dis 2004 0.75
79 Screening for HIV. Ann Intern Med 2005 0.75
80 HIV testing practices among New England college health centers. AIDS Res Ther 2013 0.75
81 Routine, not risk-based, human immunodeficiency virus testing is the way to go. J Infect Dis 2003 0.75
82 Risk factors for non-communicable diseases in prison populations. Lancet 2012 0.75
83 HIV counseling and testing among injection drug users needs to continue. Am J Public Health 2007 0.75
84 Point of view: the rapid spread of HIV among minority communities in the United States: a call to action. Med Health R I 2003 0.75
85 Antiretroviral rounds. A communication conundrum. AIDS Clin Care 2005 0.75
86 Spontaneous perforation of the terminal ileum in an AIDS patient on highly active antiretroviral therapy with disseminated non-tuberculous mycobacterial infection. Int J Infect Dis 2008 0.75
87 Confronting the clinical uncertainty regarding syphilis. AIDS Clin Care 2003 0.75